Methylene Blue (low-dose)
Research Reliability -
A century-old dye repurposed at very low doses as a mitochondrial electron carrier and emerging cognitive compound.
Appetite
Mood
Sleep
Methylene Blue (low-dose)
Description
Methylene blue has been used clinically since the early 1900s, but at very low ("low-dose") amounts it acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing damaged complexes I and III to support ATP production — a mechanism that has generated real interest in the biohacking and longevity community for cognitive and energy effects. Low-dose use is the operative phrase here: the dose-response curve is U-shaped, meaning higher amounts that help in animal models of disease can become pro-oxidant and harmful, and only pharmaceutical-grade (USP) methylene blue, not aquarium or industrial-grade product, should ever be considered. It also inhibits MAO enzymes, creating a serious interaction risk with serotonergic drugs and supplements.
Effects
First dose
subtle cognitive lift for some within hours
Same day
Caution
How It Feels
At genuinely low doses some report a mild cognitive or energy lift within hours; it also famously turns urine blue-green, which is expected. Purity is critical, so only pharmaceutical USP grade is appropriate, and it must never be combined with serotonergic medications. This is a compound to approach carefully and with guidance.
Evidence
Evidence Strength
Preliminary (limited / small human data)
Caveats
This is one small acute imaging study, not a body of clinical outcome trials. Methylene blue has MAOI-like serotonergic activity and can cause dangerous interactions with SSRIs, SNRIs, and other serotonergic drugs; broad nootropic, mitochondrial, and longevity claims substantially outrun the human evidence.
Usage
Commonly Referenced Starting Amount
Reference only — no consumer dose
Commonly Referenced Amount
Methylene blue is an FDA-approved injectable drug, not a dietary supplement, with serious interaction risks (serotonin syndrome with SSRIs/MAOIs, hemolysis in G6PD deficiency). It is not something to self-dose from a wellness database.
Referenced Upper Limit
Not applicable outside clinical or research supervision
Onset
Hours (cognitive); requires pharmaceutical-grade USP source
Biomarkers to Track
Subjective
(Daily)
Mental clarity and focus (1–10)
Energy levels
Urine color change (expected, harmless blue-green tint)
Objective
(Quarterly)
G6PD screening (before first use)
Methemoglobin level (if monitoring clinically)
Cognitive testing battery (reaction time, working memory)
Has MAOI-like activity, so combined with serotonergic drugs it can cause dangerous serotonin syndrome. Only pharmaceutical USP grade is appropriate.
Anyone on antidepressants or serotonergic drugs, and people with G6PD deficiency.
Using non-pharmaceutical grade, dosing too high, and combining it with SSRIs.
Disclaimer
This information is for educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any new supplement, especially if you are pregnant, nursing, taking medication, or managing a health condition.
Rodriguez P et al. (2016). Radiology, 281(1), 516-526. RCT (low-dose methylene blue, fMRI memory/attention, n=26). PMID: 27379190. DOI: 10.1148/radiol.2016152893.
MORE SUPPLEMENTS LIKE THIS
